161 related articles for article (PubMed ID: 18600563)
1. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data.
Sweeney ZK; Klumpp K
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):458-70. PubMed ID: 18600563
[TBL] [Abstract][Full Text] [Related]
2. IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection.
Klibanov OM; Kaczor RL
Curr Opin Investig Drugs; 2010 Feb; 11(2):237-45. PubMed ID: 20112173
[TBL] [Abstract][Full Text] [Related]
3. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.
Sweeney ZK; Kennedy-Smith JJ; Wu J; Arora N; Billedeau JR; Davidson JP; Fretland J; Hang JQ; Heilek GM; Harris SF; Hirschfeld D; Inbar P; Javanbakht H; Jernelius JA; Jin Q; Li Y; Liang W; Roetz R; Sarma K; Smith M; Stefanidis D; Su G; Suh JM; Villaseñor AG; Welch M; Zhang FJ; Klumpp K
ChemMedChem; 2009 Jan; 4(1):88-99. PubMed ID: 19006142
[TBL] [Abstract][Full Text] [Related]
4. [Non-nucleoside reverse transcriptase inhibitors].
Joly V; Yeni P
Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953
[TBL] [Abstract][Full Text] [Related]
5. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
6. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
Arastéh K; Rieger A; Yeni P; Pozniak A; Boogaerts G; van Heeswijk R; de Béthune MP; Peeters M; Woodfall B
Antivir Ther; 2009; 14(5):713-22. PubMed ID: 19704175
[TBL] [Abstract][Full Text] [Related]
7. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.
Adams J; Patel N; Mankaryous N; Tadros M; Miller CD
Ann Pharmacother; 2010 Jan; 44(1):157-65. PubMed ID: 19996323
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
Ghosn J; Chaix ML; Delaugerre C
AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
[TBL] [Abstract][Full Text] [Related]
9. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
de Béthune MP
Antiviral Res; 2010 Jan; 85(1):75-90. PubMed ID: 19781578
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
11. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
12. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
D'Cruz OJ; Uckun FM
J Antimicrob Chemother; 2006 Mar; 57(3):411-23. PubMed ID: 16431862
[TBL] [Abstract][Full Text] [Related]
13. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Silvestri R
Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
[TBL] [Abstract][Full Text] [Related]
15. New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.
Jayaweera D; Dilanchian P
Expert Opin Pharmacother; 2012 Dec; 13(18):2601-12. PubMed ID: 23176566
[TBL] [Abstract][Full Text] [Related]
16. Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection.
Fernández-Montero JV; Vispo E; Anta L; de Mendoza C; Soriano V
Expert Opin Pharmacother; 2012 May; 13(7):1007-14. PubMed ID: 22519768
[TBL] [Abstract][Full Text] [Related]
17. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
Boone LR
Curr Opin Investig Drugs; 2006 Feb; 7(2):128-35. PubMed ID: 16499282
[TBL] [Abstract][Full Text] [Related]
18. The search for potent, small molecule NNRTIs: A review.
Prajapati DG; Ramajayam R; Yadav MR; Giridhar R
Bioorg Med Chem; 2009 Aug; 17(16):5744-62. PubMed ID: 19632850
[TBL] [Abstract][Full Text] [Related]
19. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.
Garvey L; Winston A
Expert Opin Investig Drugs; 2009 Jul; 18(7):1035-41. PubMed ID: 19548857
[TBL] [Abstract][Full Text] [Related]
20. Two new NNRTIs enter the pipeline.
Dalton P
Proj Inf Perspect; 2008 Sep; (46):13. PubMed ID: 19048672
[No Abstract] [Full Text] [Related]
[Next] [New Search]
